Carregant...
Melanoma driver mutations and immune therapy
Melanoma harbors recurrent oncogenic driver mutations in BRAF and NRAS, but these mutations' impact on immunotherapy outcomes is unclear. We assessed 229 patients treated with immunotherapy, and found that clinical outcomes were largely superior in those with NRAS mutations. Herein, we discuss...
Guardat en:
| Publicat a: | Oncoimmunology |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4910708/ https://ncbi.nlm.nih.gov/pubmed/27467925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1051299 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|